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Abstract
Background: Hyperhomocysteinemia, characterized by increased plasma homocysteine level, is associated with an
increased risk of atherosclerosis. On the contrary, patients with Down syndrome appear to be protected from the
development of atherosclerosis. We previously found a deleterious effect of hyperhomocysteinemia on expression of
DYRK1A, a Down-syndrome-associated kinase. As increased expression of DYRK1A and low plasma homocysteine level have
been associated with Down syndrome, we aimed to analyze the effect of its over-expression on homocysteine metabolism
in mice.
Methodology/Principal Findings: Effects of DYRK1A over-expression were examined by biochemical analysis of methionine
metabolites, real-time quantitative reverse-transcription polymerase chain reaction, and enzyme activities. We found that
over-expression of Dyrk1a increased the hepatic NAD(P)H:quinone oxidoreductase and S-adenosylhomocysteine hydrolase
activities, concomitant with decreased level of plasma homocysteine in three mice models overexpressing Dyrk1a.
Moreover, these effects were abolished by treatment with harmine, the most potent and specific inhibitor of Dyrk1a. The
increased NAD(P)H:quinone oxidoreductase and S-adenosylhomocysteine hydrolase activities were also found in
lymphoblastoid cell lines from patients with Down syndrome.
Conclusions/Significance: Our results might give clues to understand the protective effect of Down syndrome against
vascular defect through a decrease of homocysteine level by DYRK1A over-expression. They reveal a link between the
Dyrk1a signaling pathway and the homocysteine cycle.
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Introduction
Homocysteine (Hcy) is a sulfur-containing amino acid formed
during the intracellular conversion of methionine via the
adenosylated compounds S-adenosylmethionine (SAM) and S-
adenosylhomocysteine (SAH). The formation of SAM is catabo-
lized by methionine adenosyl transferase (MAT). Once Hcy is
formed, it may be recycled to methionine after remethylation by
two different pathways. The first one involves methionine synthase
(MS), an enzyme that uses vitamin B12 (cobalamin) as an essential
cofactor and 5-methyltetrahydrofolate as the methyl donor. The
5-methyltetrahydrofolate is generated by 5, 10-methylene tetra-
hydrofolate reductase (MTHFR) [1]. The second pathway, which
occurs in liver and kidney, involves the enzyme betaine-
homocysteine methyltransferase (BHMT). Hcy may also undergo
condensation with serine to form cystathionine, which is catalyzed
by the vitamin B6-dependent enzyme cystathionine beta synthase
(CBS), the first enzyme involved in the transsulfuration pathway.
Cystathionine is subsequently hydrolysed to form cysteine which
can be, in turn, incorporated into protein or used to synthesize the
antioxidant glutathione. Hcy can also turn back to SAH via
reversal of the SAH hydrolase (SAHH) reaction [1].
Elevated plasma Hcy levels are well-recognized as an indepen-
dant risk factor for atherosclerosis in the coronary, cerebrovascular
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7540and peripheral arterial circulation [2]. Conversely, although Down
syndrome (DS) is associated with a great variety of phenotypes, the
incidence of atherosclerotic vascular disease seems to be low [3,4].
Even if the coronary arteries of DS patients were not completely
free of atherosclerosis, it was milder than in other mentally
retarded patients and in control subjects of the same age [5].
Moreover, healthy old DS patients showed some classical
biochemical risk factors for atherosclerosis but did not suffer from
clinical cardiovascular alterations [6]. Because many genetic
factors can be related to this reduction, the reasons for this
apparent protection against atherosclerosis remain unclear.
DYRK1A, which gene is localized on human chromosome 21,
is a protein kinase that belongs to an evolutionarily conserved
family of proteins known as DYRKs (dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase) involved in diverse functions
ranging from development, growth to apoptosis [7–9]. On the one
hand, we recently reported a reduction of Dyrk1a protein level in
liver of CBS-deficient mice, a murine model of hyperhomocystei-
nemia [10], suggesting a link between DYRK1A related pathways
and the Hcy cycle. On the other hand, an increased expression of
DYRK1A and low plasma Hcy levels have been associated with
DS [6,11–13]. To analyze further the relation between DYRK1A
and Hcy metabolism, we used four transgenic models to
demonstrate the effect of the over-expression of Dyrk1a on Hcy
metabolism: a model of hyperhomocysteinemia due to CBS
deficiency [14] and three models with duplications of increasing
complexity and over-expression of Dyrk1a [15]: a BAC transgenic
with one copy of the murine Dyrk1a gene; a YAC transgenic for a
human chromosome 21 fragment carrying five genes including
DYRK1A; a partial trisomy 16 mouse carrying an extra copy of a
region of MMU16 syntenic for a region of HSA21 between
Mrpl39 and Znf295 containing 138 genes (also including Dyrk1a)
and considered to be a valid mouse model of human Down
syndrome [16].
Results
DYRK1A over-expression reduces the plasma Hcy levels
in mice
In order to analyze the over-expression of DYRK1A on plasma
Hcy levels, we used three models of mice, which overexpress not
only the murine gene, but also the human one. The transgenic line
(Tg) 152F7 contains five human genes including DYRK1A. The
Tg 189N3 contains the murine orthologue of DYRK1A. The
Ts65Dn line is the most complete of the commonly available
mouse models of the mouse partial trisomy 16 and exhibits
morphological and biochemical changes seen in DS [17,18]. We
first analyzed the overexpression of DYRK1A in liver of mice.
Male Tg 152F7 mice, two months of age, showed a two-fold
increase in gene expression of DYRK1A in the liver compared to
non-transgenic mice (Fig. 1A). Female Tg 189N3 mice, two
months of age, showed a 1.4-fold increase in gene expression of
Dyrk1a compared to non-transgenic mice (Fig. 1B). Male Ts65Dn
mice, six months of age, showed a 1.6-fold increase in gene
expression of Dyrk1a compared to non-transgenic mice (Fig. 1D).
Commensurate with the mRNA expression, protein expression of
DYRK1A was 1.3 fold, 1.6 fold and 1.7 fold higher in liver of Tg
152F7, Tg 189N3, and Ts65Dn mice respectively (Fig. 2 and
Figs. 1C, 1E).
In order to show the effect of over-expression of DYRK1A on
plasma Hcy level, serum of Tg 152F7 and heterozygous CBS-
deficient (Cbs
+/2) mice crossbred with Tg 152F7 mice was analyzed
by HPLC. Tg 152F7 mice (Cbs
+/+ T g1 5 2 F 7 ;F i g .3 Aa n dT a b l e1 )
have a Hcy level 1.4-foldlower than those of Cbs
+/+mice(Cbs
+/+Tg -;
Fig. 3A and Table 1). As previously shown [10], Dyrk1a protein
expression was decreased in liver of Cbs
+/2 mice (Cbs
+/2 Tg -; Fig. 2),
compared with protein extracted from Cbs
+/+ mice (Cbs
+/+ Tg -;
Fig. 2). Cbs
+/2 mice crossbred with Tg 152F7 mice (Cbs
+/2 Tg 152F7;
Fig. 2) also showed a 1.3 fold-increased hepatic expression of
DYRK1A compared to Cbs
+/2 mice (Cbs
+/2 Tg -; Fig. 2). As
expected, Hcy level of Cbs
+/2 mice (Cbs
+/2 Tg -; Fig. 3A) was 1.7-fold
higher than those of Cbs
+/+ mice (Cbs
+/+ Tg -; Fig. 3A). However,
Cbs
+/2 mice crossbred with Tg 152F7 mice (Cbs
+/2 Tg 152F7;
Fig. 3A) have a Hcy level 1.4-fold lower than those of Cbs
+/2 mice
(Cbs
+/2 Tg -; Fig. 3A). Tg 189N3 and Ts65Dn mice have also a Hcy
level 2.35-fold and 1.4-fold lower than those of non-transgenic mice
respectively (Table 1). These results emphasize the effect of over-
expression of DYRK1A on plasma Hcy level, not only in case of
hyperhomocysteinemia but also in the context of DS.
DYRK1A over-expression modulates SAHH activity
AsCBSisa key enzyme ofHcy metabolism[19,20], we first assayed
the CBS activity in liver samples of mice. As expected, Cbs
+/2 mice
(Cbs
+/2 Tg -; Fig. 3B) showed a significant decrease of CBS activity
when compared with Cbs
+/+ mice (Cbs
+/+ Tg -; Fig. 3B). Tg 152F7
mice (Cbs
+/+ Tg 152F7; Fig. 3B) have the same CBS activity than that
of Cbs
+/+ mice (Cbs
+/+ Tg -; Fig. 3B). However, Cbs
+/2 mice crossbred
with Tg 152F7 mice (Cbs
+/2 Tg 152F7; Fig. 3B) showed a decrease of
CBS activity like Cbs
+/2 mice when compared with Cbs
+/+ mice. Tg
189N3 (11064versus 10067; p,0.26 by Student’s ttest n=5foreach)
and Ts65Dn (11167 versus 10063; p,0.17 by Student’s t test n=5
for each) mice have also the same CBS activity than that of non-
transgenic mice. Then our results show that dyrk1a overexpression
has no effect on CBS activity.
As Hcy can revert back to SAH via the SAHH mediated reverse
reaction, we assayed SAHH activity in mouse liver. Tg 152F7
mice (Cbs
+/+ Tg 152F7; Fig. 3C) showed an increase of SAHH
activity when compared with Cbs
+/+ mice (Cbs
+/+ Tg -; Fig. 3C).
Moreover, Cbs
+/2 mice crossbred with Tg 152F7 mice (Cbs
+/2 Tg
152F7; Fig. 3C) counteracted the decreased SAHH activity when
compared with Cbs
+/2 mice (Cbs
+/2 Tg -; Fig. 3C). Tg 189N3
(Fig. 4A) and Ts65Dn (Fig. 4B) mice also showed an increased
SAHH activity when compared to non-transgenic mice. We also
determined the hepatic levels of SAM and SAH in Tg mice
overexpressing DYRK1A and found that levels of SAM and SAH
in liver of Tg 152F7 and Tg189N3 did not differ from non-
transgenic mice (Table 1). However, we found a decreased level of
SAM in liver of Ts65Dn mice compared to non-transgenic mice,
leading to decreased SAM to SAH ratio (Table 1).
In order to determine if other enzymes of the methionine and
folate cycles are altered, we assayed the mRNA expression of the
major enzymes involved in the metabolism of Hcy in the liver of
Tg 189N3. We found that even if the Mat1a mRNA expression
was not affected in Tg 189N3 mice (data not shown), the Bhmt, Ms
and Mthfr mRNA expression were increased compared to non-
transgenic mice (Table 2). However, the Sahh mRNA expression
was decreased in Tg 189N3 mice compared to non-transgenic
mice (Table 2).
Plasma Hcy level is negatively correlated with hepatic
DYRK1A expression and SAHH activity
We previously observed a negative correlation between plasma
Hcy levels and hepatic DYRK1A expression, which emphasizes
the effect of hyperhomocysteinemia on DYRK1A expression [10].
Then we investigated if there are any links between Hcy
concentration, hepatic DYRK1A protein expression and hepatic
SAHH activity. We observed a significant negative correlation
between plasma Hcy level and not only hepatic DYRK1A protein
DYRK1A and Homocysteine
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activity (r=20.61, p,0.006; Fig. 5B). Moreover, hepatic
DYRK1A protein expression was also positively correlated with
hepatic SAHH activity (r=0.47, p,0.05; Fig. 5C). Multivariate
analysis revealed a negative correlation between plasma Hcy level
and hepatic DYRK1A protein expression and SAHH activity
Figure 1. Hepatic DYRK1A mRNA and protein expression in liver of transgenic mice. Relative expression of DYRK1A gene was based on Q-
PCR data and protein expression was determined by normalization of the density of images from DYRK1A with that of b-actin of the same blot. The
values of Tg 152F7, Tg189N3 and Ts65Dn were normalized to the mean Tg – mice from each lines. The blots are representative of three independent
experiments. Data correspond to means 6 SEM and the statistical analysis was done by Student’s unpaired t-tests. n=number of mice.
doi:10.1371/journal.pone.0007540.g001
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hepatic DYRK1A protein expression and low hepatic SAHH
activity in mice.
DYRK1A over-expression modulates NQO1 activity
Wefoundthatthe SahhmRNAexpressionnotonlywasdecreased
in Tg 189N3 mice (Table 2) but also in Ts65Dn (69.665.6 versus
102.168.5; p,0.005 by Student’s t test n=4 for each mouse)
compared to non-transgenic mice. The increased activity of
NAD(P)H:quinone oxidoreductase (NQO1) is followed by an
increase of a by-product of the enzyme reaction, NAD+, which is
a cofactor of SAHH [21]. In order to determine if SAHH is a direct
or an indirect target of Dyrk1a, we analyzed the activity of NQO1
in liver oftransgenicmice. We found an increased activity ofNQO1
not only inTg152F7(Cbs
+/+ Tg 152F7;Fig.3D), Tg 189N3butalso
in Ts65Dn mice compared to non-transgenic mice (Fig. 3D and
Table 3). Moreover, Cbs
+/2 mice crossbred with Tg 152F7 mice
(Cbs
+/2 Tg 152F7; Fig. 3D) counteracted the decreased NQO1
activity when compared with Cbs
+/2 mice (Cbs
+/2 Tg -; Fig. 3D).
Commensurate with the increased activity, mRNA expression of
NQO1 was 1.8 fold higher in liver of Tg 189N3 and Ts65Dn mice
compared to non-transgenic mice (Table 3).
Harmine inhibits the effects of DYRK1A over-expression
on SAHH activity
In order to determine if the effects are dependent on Dyrk1a
kinase activity, we treated Tg 189N3 mice with harmine, the most
potent and specific inhibitor of Dyrk1a [22,23]. Even non-
transgenic mice treated with harmine (Tg – Harmine, Fig. 6A)
showed an increased SAHH activity compared to untreated non-
transgenic mice (Tg – Vehicle, Fig. 6A), Tg 189N3 mice treated
with harmine (Tg 189N3 Harmine, Fig. 6A) had the same
increased activity than that of non-transgenic mice treated with
harmine (Tg – Harmine, Fig. 6A), which shows that treatment
with harmine prevents the increase of SAHH activity in Tg 189N3
mice. Moreover, even if harmine treatment has no effect on
NQO1 in non transgenic mice (Tg – Harmine, Fig. 6B), treatment
with harmine in Tg 189N3 mice (Tg 189N3 Harmine, Fig. 6B)
reduced NQO1 activity compared to non treated Tg 189N3 mice
(Tg 189N3 Vehicle, Fig. 6B).
To confirm the implication of Dyrk1a on Hcy level, we also
assayed plasma Hcy levels in harmine-treated non-transgenic
and Tg 189N3 mice. There was a trend towards a 1.4 fold increase
of plasma Hcy concentration in harmine treated Tg 189N3
(Tg 189N3 Harmine, Fig. 6C) compared to non-treated Tg 189N3
mice (Tg 189N3 Vehicle, Fig. 6C) although this was not
statistically significant.
SAHH and NQO1 activities were increased in
lymphoblastoid cell lines
In order to determine whether the activities observed in mice
does apply to humans, we also analyzed the SAHH and NQO1
activity in lymphoblastoid cell lines (LCLs) from patients with DS.
We first confirmed that LCLs from patients with DS (T21, Table 4)
overexpressed 1.5 fold DYRK1A at the mRNA and protein level
compared to LCLs from control individuals (control, Table 4). We
not only found an increased SAHH activity but also a decreased
mRNA SAHH expression in LCLs from patients with DS
compared to LCLs from control individuals (Table 4). Moreover,
the NQO1 activity was also increased in LCLs from patients with
DS, concomitant with an increased mRNA expression (Table 4).
Discussion
Elevated plasma Hcy level is well recognized as an important
vascular risk factor and atherosclerosis in the coronary, cerebro-
vascular and peripheral arterial circulation, even if the degree of
hyperhomocysteinemia is moderate [2]. On the contrary, adults
with Down syndrome seem to be protected against atherosclerosis,
despite having elevated risk factors, such as elevated total body fat,
higher levels of triglycerides and C-reactive protein, and lower
levels of moderate to vigorous physical activity [24]. As we found a
negative correlation between plasma Hcy levels and hepatic
DYRK1A expression which underlines the effect of hyperhomo-
cysteinemia on DYRK1A expression [10], we decided to analyze
the over-expression of DYRK1A on Hcy metabolism. Here we
show that overexpression of DYRK1A diminishes the plasma Hcy
level. This result was obtained with different murine models which
contain the human or the murine gene, with duplications of
increasing complexity and over-expression of Dyrk1a. Therefore,
we see an effect of Hcy level on DYRK1A expression [10], but
also an effect of DYRK1A expression on Hcy level, which is
Figure 2. DYRK1A protein expression in liver of CBS-deficient
mice crossbred with 152F7 transgenic mice. (A) Western
immunoblots showing DYRK1A expression in liver of wild type mice
(Cbs
+/+ Tg -), heterozygous mice (Cbs
+/2 Tg -), 152F7 transgenic mice
(Cbs
+/+ Tg 152F7), and heterozygous mice crossbred with 152F7
transgenic mice (Cbs
+/2 Tg 152F7). Proteins were subjected to
immunoblot analysis using antibodies specific to DYRK1A (85.5 kDa).
After stripping, the membranes were reprobed with anti-b-actin
antibody (41.7 kDa) for the control. (B) Relative protein expression
was determined by normalization of the density of images from
DYRK1A with that of b-actin of the same blot. The values of Cbs
+/2 Tg -,
Cbs
+/+ Tg 152F7, or Cbs
+/2 Tg 152F7 were normalized to the mean of
Cbs
+/+ Tg - mice. The blots are representative of three independent
experiments. Data correspond to means 6 SEM and the statistical
analysis was done with one-way ANOVA followed by Student’s
unpaired t-tests. n=number of mice.
doi:10.1371/journal.pone.0007540.g002
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PLoS ONE | www.plosone.org 4 October 2009 | Volume 4 | Issue 10 | e7540underlined by the correlation between plasma Hcy level and
hepatic DYRK1A protein expression (10 and Figure 5).
As increased expression of DYRK1A and low plasma Hcy levels
have been associated with DS [6,11–13], we also analyzed the
contributionofDYRK1AonHcylevelsinamousetrisomiccomplex,
the Ts65Dn mice. We found an increased expression of DYRK1A in
liver and a decreased level of plasma Hcy level in Ts65Dn. DYRK1A
and CBS are two genes located on chromosome 21. Our results show
that over-expression of DYRK1A has no effect on CBS activity,
which is in agreement with the hepatic SAM levels (an allosteric
activator of CBS). It has been demonstrated that DS children have
increased cystathionine level relative to normal children, consistent
with over-expression of the CBS gene present on human chromo-
some 21 and mouse chromosome 17 [11]. On the one hand, the
over-expression of CBS in DS is the predominant mechanism to
explain the decrased plasma Hcy level in DS patients [11]. On the
other hand, the DYRK1A over-expression likely plays a role on
decreased plasmaHcy level in DS patients however, to a lesser extent.
We showed that over-expression of DYRK1A increases the
SAHH activity not only in mice, but also in LCLs obtained from
DS patients. Moreover, treatment with harmine, the most potent
and specific inhibitor of Dyrk1a [22,23], demonstrates that the
increased SAHH activity depends on Dyrk1A kinase activity. We
also established a correlation between plasma Hcy level, hepatic
DYRK1A protein expression and hepatic SAHH activity.
However, the increased hepatic SAHH activity was not associated
with statistical difference in hepatic SAH levels. A previous study
showed a lower concentration of plasma Hcy and SAH levels in
DS children than in plasma of control subjects [11]. Galletti et al.
also demonstrated that the intracellular concentration of SAH is
significantly reduced in DS erythrocytes, paralleling the low
plasma Hcy levels, and the intracellular SAM concentration is the
same as in the control cells [13]. Therefore the diminution of SAH
levels could be due to other genes located on chromosome 21. We
found a decreased hepatic SAM levels, associated with a decrease
of the SAM/SAH ratio in Ts65Dn, which suggests an altered
Figure 3. Plasma Hcy level is decreased in 152F7 transgenic mice and in CBS-deficient mice crossbred with 152F7 transgenic mice.
(A) Plasma Hcy level, (B) hepatic CBS, (C) SAHH and (D) NQO1 activity in wild type mice (Cbs
+/+ Tg -), heterozygous mice (Cbs
+/2 Tg -), 152F7
transgenic mice (Cbs
+/+ Tg 152F7), and heterozygous mice crossbred with 152F7 transgenic mice (Cbs
+/2 Tg 152F7). The values were normalized to
the mean of Cbs
+/+ Tg - mice. Data correspond to means 6 SEM and the statistical analysis was done with one-way ANOVA followed by Student’s
unpaired t-tests. n=number of mice.
doi:10.1371/journal.pone.0007540.g003
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mice. Interestingly, Ts65Dn mice also contain three copies of
DNMTa1 gene, which encodes for a DNA methyltransferase. The
over-expression of this DNA methyltransferase could decrease
SAM level and the SAM/SAH ratio in liver of Ts65Dn mice,
which could influence the methylation index and then the gene
expression.
SAHH cleaves SAH to adenosine and Hcy, but this reaction is
easily reversible by the same enzyme [25]. Although the
equilibrium dynamics of the SAHH reaction strongly favor SAH
formation, under physiological conditions, the rapid metabolism of
SAHH end products Hcy (via transsulfuration and remethylation
pathways) and adenosine (via the adenosine deaminase or
adenosine kinase) drive the SAHH reaction in the hydrolysis
direction. The activation of the SAHH activity in the reverse
direction would be expected to promote the diminution of Hcy.
The finding that DYRK1A over-expression activated SAHH
activity is novel and is also consistent with no limitation of the
remethylation pathway. We found an increased expression of the
three enzymes implicated in the remethylation pathway in liver of
Tg189N3 mice. However, the SAHH expression was decreased
not only in liver of Tg 189N3 and Ts65Dn mice, but also in LCLs
from DS patients. Because SAHH transcripts were decreased, the
finding of increased SAHH activity must represent a post-
transcriptional modification of the enzyme. The activation of
SAHH activity can be due to a direct or an indirect mechanism.
We found an increased activity of NQO1 not only in liver of Tg
152F7, Tg 189N3 and Ts65Dn mice, but also in LCLs obtained
from DS patients. Moreover, treatment with harmine demon-
strates that the increased NQO1 activity depends on Dyrk1A
kinase activity. The increased activity of NQO1 is followed by an
increase of a by-product of the enzyme reaction, NAD+, which is a
cofactor of SAHH [21]. NQO1 is an inducible enzyme, and its
overexpression protects cells against cell death [26]. The cell’s
major strategy of coping with oxidative stress is to increase the
anti-oxidative potential by upregulating defense enzymes through
activation of the nuclear factor-E2-related factor-2 (Nrf2). Nrf2
can activate many phase II detoxifying and antioxidant genes
including NQO1 [27]. Nrf2 dissociates from the cytoskeletal
binding protein KEAP1 and translocates to the nucleus in
response to oxidative stress. It has been demonstrated that the
PI3K/Akt pathways facilitate the release of NRF2 from KEAP1
and its subsequent translocation, and regulate ROS-dependent
Nrf2 activation [28]. Previous results have shown that phosphor-
ylation of protein kinase Akt was increased in Ts65Dn mice, and
we found an increased hepatic NQO1 activity in these mice [29].
Then over-expression of DYRK1A could modulate the hepatic
SAHH activity through an indirect mechanism initiated by its
serine/threonine kinase activity.
In conclusion, our results might give clues to understand the
protective effect of DS against vascular defect through a decrease
of Hcy level, and a link between metabolomics and signalling
pathways.
Methods
Mice and genotyping
Mice were maintained in a controlled environment with
unlimited access to food and water on 12 h light/dark cycle. All
procedures were carried out in accordance with internal guidelines
of the French Agriculture Ministry for animal handing. Number of
Table 1. Plasma Hcy levels, hepatic SAM and SAH
concentrations, and hepatic SAM/SAH ratio in transgenic
mice.
Genotype
(n=number of mice)
Hcy
(mM)
SAM
(nmol/g)
SAH
(nmol/g) SAM/SAH
Tg –
(n=4)
3.960.3 79.569.1 52.763.1 1.560.2
Tg 152F7
(n=6)
2.960.2* 73.266.4 42.464.1 1.860.2
Tg –
(n=5)
4.760.6 64.8610.3 35.763.3 1.860.2
Tg 189N3
(n=5)
260.1
{ 67.7 66.5 35.563.1 260.2
Tg –
(n=7)
2.660.1 5263.8 4463.1 1.260.1
Ts65Dn
(n=6)
1.960.3* 35.663.5
{ 51.463.8 0.760.1
{
Data correspond to means 6 SEM and the statistical analysis was done by
Student’s unpaired t-tests. * p,0.04;
{ p,0.01;
{p,0.002.
doi:10.1371/journal.pone.0007540.t001
Figure 4. Hepatic SAHH activity is increased in Tg 189N3 and Ts65Dn transgenic mice. SAHH activity in (A) Tg 189N3 and (B) Ts65Dn
transgenic mice. The values were normalized to the mean of Tg – mice from each line. Data correspond to means 6 SEM and the statistical analysis
was done by Student’s unpaired t-test. n=number of mice.
doi:10.1371/journal.pone.0007540.g004
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Tg189N3 mice.
Genotype
(n=number of mice)
SAHH
(% of control)
BHMT
(% of control)
MS
(% of control)
MTHFR
(% of control)
Tg –
(n=4)
104614 100661 0 0 64 103611
Tg 189N3
(n=4)
55612
{ 242645
{ 8916195
{ 7266330*
The values of Tg189N3 were normalized to the mean Tg – mice. Data correspond to means 6 SEM and the statistical analysis was done by Student’s unpaired t-tests.
n=number of mice. *p=0.068;
{ p, 0.03.
doi:10.1371/journal.pone.0007540.t002
Figure 5. Plasma Hcy level, DYRK1A protein expression and SAHH activity are correlated. Hepatic DYRK1A expression and SAHH activity
are presented as percent of Cbs
+/+ Tg – mice. Correlation of plasma Hcy level vs. (A) hepatic DYRK1A protein expression or (B) hepatic SAHH activity.
Increasing levels of plasma Hcy and hepatic DYRK1A protein expression or SAHH activity are negatively correlated at p,0.04 and p,0.006 with a
r=20.48 and r=20.61 respectively. Correlation of hepatic DYRK1A protein expression vs. SAHH activity (C). Increasing levels of hepatic DYRK1A
protein expression and hepatic SAHH activity are positively correlated at p,0.05 with a r=0.47. (D) Graph of PCA. The three quantitative variables
corresponding of plasma Hcy level, hepatic DYRK1A protein expression and hepatic SAHH activity are represented by vectors.
doi:10.1371/journal.pone.0007540.g005
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for targeted disruption of the Cbs gene (Cbs
+/2) were generously
donated by Dr. N. Maeda (Department of Pathology, University
of North Carolina, Chaped Hill, NC, USA) [14]. Cbs
+/2 mice, on
a C57BL/6 background were obtained by mating male Cbs
+/2
mice with female wild-type C57BL/6 (Cbs
+/+) mice. DNA isolated
from 4 week-aged mice tail biopsies was subjected to genotyping
of the targeted CBS allele using a polymerase chain reaction
(PCR) assay [14]. The human yeast artificial chromosome 152 F7
(YAC-152F7) strain has been previously described [30]. This
transgenic line (Tg 152F7) contains the genes PIGP, TTC3,
DSCR9, DSCR3 and DYRK1A. The YAC-152F7 line, which
was constructed in an FVB/N background, was backcrossed on a
C57BL/6 background. Genotyping was performed by PCR using
specific human primers [30]. Cbs
+/2 and Tg 152F7 mice, on the
same background, were crossbred. Male from each genotype from
the same litter, two months of age, were used. The murine
bacterial artificial chromosome 189 N3 (BAC-189N3) strain has
been constructed by electroporating HM-1 embryonic stem (ES)
Table 3. Relative expression of NQO1 gene based upon Q-
PCR data and NQO1 activity obtained from non-transgenic
and Tg189N3 and Ts65Dn mice.
Genotype
(n=number of mice)
mRNA expression
(% of control)
activity
(% of control)
Tg - 100.764
(n=4)
100620,9
(n=3)
Tg 189N3 177.3637.3*
(n=3)
379.5 674.2*
(n=4)
Tg – 100.965
(n=4)
100627,2
(n=5)
Ts65Dn 176.3622.6
{
(n=4)
212632,5*
(n=5)
The values of Tg189N3 and Ts65Dn were normalized to the mean Tg – mice
from each line. Data correspond to means 6 SEM and the statistical analysis
was done by Student’s unpaired t-tests. n=number of mice. *p,0.03;
{ p,0.01.
doi:10.1371/journal.pone.0007540.t003
Figure 6. Effects of harmine on hepatic SAHH and NQO1 activities, and on plasma Hcy levels in Tg 189N3 mice. Hepatic SAHH (A) and
NQO1 (B) activities are presented as percent of untreated (Vehicle) non-transgenic (Tg –) mice activities. (C) Plasma Hcy level. Data correspond to
means 6 SEM and the statistical analysis was done with one-way ANOVA followed by Student’s unpaired t-test. n=number of mice.
doi:10.1371/journal.pone.0007540.g006
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overexpression of Dyrk1a, and injected into blastocysts (J Delabar,
personal communication). Female Tg 189N3 mice and control
from the same litter, two months of age, were used. Ts65Dn mice
possess a third copy of a region of mouse chromosome 16 from App
to Mx1, orthologous to the DS critical region of HSA 21 [31].
Male Ts65Dn mice and control, from the same litter, six months
of age, were used.
Harmine treatment
Mice were injected intraperitoneally overnight, with 10 mg/kg
of harmine hydrochloride hydrate (Fisher Scientific, Illkirch,
France) dissolved in 0.9% NaCl. The next morning, mice were
injected once more for 1 hour. Control mice were injected with
0.9% NaCl.
Preparation of serum samples, tissue collection, and
plasma total Hcy assay
At the time of sacrifice, blood samples were collected into tubes
containing a 1/10 volume of 3.8% sodium citrate, placed on ice
immediately. Plasma was isolated by centrifugation at 2500 g for
15 min at 4uC. Liver was harvested, snap-frozen and stored at
280uC until use. Plasma total Hcy was assayed by using the
fluorimetric high-performance liquid chromatography method
described by Fortin and Genest [32]. The inter- and intra-assay
coefficients of variation for mean tHcy level were 4.2% and 6.3%
respectively and the linearity was from 1 to 100 mM [33].
Cell Lines and Culture Conditions
Epstein–Barr virus-transformed lymphoblastoid cell lines (LCLs)
are derived from healthy individuals and unrelated DS patients,
recruited from the Institut Je ´ro ˆme Lejeune (Paris, France) and the
CHU Saint-Etienne (France). Written informed consent was
obtained from the participants or from their families, and the
French biomedical ethics committee gave its approval for this
study (Comite ´ de Protection des Personnes dans la Recherche
Biome ´dicale number 2003–036 and 2005–06). DS was confirmed
by karyotyping before and after Epstein–Barr virus transforma-
tion. Culture media consisted of Opti-MEM with GlutaMax
(Invitrogen, Cergy, France) supplemented with 5% fetal bovine
serum from a unique batch and 1% penicillin and streptomycin
mix (10,000 U/mL). Cell lines were grown at 37uC in humidified
incubators, in an atmosphere of 5% CO2. Cells were harvested by
centrifugation, washed in 5 mL PBS, followed by another
centrifugation, and stored at 280uC.
Determination of hepatic SAM and SAH concentrations
Levels of SAM and SAH in liver tissues were determined by
stable isotope dilution liquid chromatography tandem mass
spectrometry in an adapted method from Gellekink et al. [34].
In brief, frozen tissues were homogenized with ice-cold perchloric
acid then centrifugated. Supernatant cleanup was performed
with solid phase extraction (SPE) columns after neutralization of
the acidified samples. The type of SPE cartridges used is
phenyl boronic acid (SPE Bond Elut – PBA, 100 mg) from Varian
(Courtaboeuf, les Ulis, France). Two isotopically labeled internal
standards were used :
13C5-SAH and D3-SAM. Analytes were
detected using the transitions m/z 399–250 (SAM), 402–250
(D3-SAM), 385–136 (SAH), 390–136 (
13C5-SAH) for quantifica-
tion and the transitions m/z 399–136 (SAM), 402–136 (D3-SAM),
385–134 (SAH), 390–134 (
13C5-SAH) for qualification. The detec-
tion limits (signal-to-noise ratio=3), estimated from the lower
calibration point, were 0.4 nmol/L for SAM and 0.6 nmol/L for
SAH. The variability of the assay expressed as CVs (n=4) were
13.3% for SAM and 9.6% for SAH with a plasma pool containing
130 nmol/L of SAM and 11 nmol/L of SAH.
Western blot analysis
Proteins preparations were subjected to SDS electrophoresis on
7.5% acrylamide gels under reducing conditions and transferred to
Hybond-C Extra membrane (GE Healthcare Europe GmbH,
Saclay, France). After transfer, membranes were blocked in 10%
nonfat dry milk in Tris-saline buffer (1.5 mM Tris, 5 mM NaCl,
0.1% Tween 20) and probed overnight at 4uC with DYRK1A
antibody (1/500) (Abnova corporation, Tebu, France). Horseradish
peroxidase-conjugated secondary antibody and Western Blotting
Luminol Reagent (Santa Cruz Biotechnology, Tebu, France) were
used to detect specific proteins. b-actin (1/4000) (Sigma-Aldrich,
France) was used as an internal control. Digitized images of the
immunoblots obtained using a LAS-3000 imaging system (Fuji
Photo Film Co., Ltd.) were used for densitometric measurements
with an image analyzer (UnScan It software, Silk Scientific Inc.).
Enzyme Activity assays
Determination of CBS activity was assayed on 400 mg of total
proteins obtained from liver samples, determined by Bradford
method, as described [35]. Proteins were incubated for 1h at 37uC
with 1 mM of propargylglycine, 0.2 mM of pyridoxal phosphate,
10 mM of L-serine, 10 mM of DL-Hcy, 0.4 mM of SAM, using
DTNB (5,59-dithiobis-(2-nitrobenzoic acid)) based-assay. All the
chemical products were obtained from Sigma (Sigma-Aldrich,
France). Determination of SAH hydrolase activity was assayed on
300 mg of total proteins obtained from liver samples or
lymphoblastoid cell lines following the protocol described by
Villanueva and Halsted [36]. Determination of NQO1 activity
was assayed on 150 mg of total proteins obtained from liver
samples or lymphoblastoid cell lines following the protocol
described by Ernster [37], modified by Benson et al. [38].
Table 4. Relative expression of DYRK1A, SAHH and NQO1 and SAHH and NQO1 activities obtained from lymphoblastoid cell lines.
Genotype
DYRK1A mRNA
expression
(% of control)
DYRK1A protein
expression
(% of control)
SAHH mRNA
expression
(% of control)
SAHH activity
(% of control)
NQO1 mRNA
expression
(% of control)
NQO1 activity
(% of control)
control 10069.3
(n=12)
10069.6
(n=16)
100619.3
(n=12)
10068.7
(n=10)
99.9611
(n=11)
100616
(n=6)
T21 150.8610.3
{
(n=12)
154.3615.6
{
(n=16)
53.866.5*
(n=12)
135.5612.8*
(n=12)
160.9614.6
{
(n=11)
228655*
(n=6)
The values of lymphoblastoid cell lines (LCLs) from patients with DS (T21) were normalized to the mean lymphoblastoid cell lines from control individuals (control). Data
correspond to means 6 SEM and the statistical analysis was done by Student’s unpaired t-tests. n=number of LCLs. * p,0.05;
{ p,0.006.
doi:10.1371/journal.pone.0007540.t004
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Total RNA was prepared from mice liver with the NucleospinH
RNA II kit (Macherey-Nagel, Hoerdt). The quantity and purity of
the RNA was assessed by measuring absorbance at 260 and
280 nm. Reverse transcription was carried out on 2 mg total RNA
as described by the manufacturer (Ambion, UK). The mRNA levels
were assessed by quantitative RT-PCR (Q-PCR). cDNA (0.4 mL)
was diluted with PCR mix (Light Cycler FastStart DNA Master
SYBR Green I Kit, Roche Diagnostics) containing a final
concentration of 3 mM MgCl2 and 0.5 mM of primers in a final
volume of 10 mL. The primers were designed by Primer 3 software.
The primers pairs were selected to yield a single amplicon based on
dissociation curves. The peptidylprolyl isomerase B (PPIB) mRNA,
the hypoxanthine phosphoribosyltransferase (HPRT) mRNA, the
fasciculation and elongation zeta protein 1 (fez), and the Zinc finger
protein (AB000468) mRNA were used as an endogenous control.
Primer sequences were given in the table 5. Q-PCR was performed
on total RNA isolated from liver of individual mice or from
individual LCLs in a Lightcycler system (Roche Diagnostics). The
thermal cycler parameters were as follows : hold for 8 min at 95uC
for one cycle followed by amplification of cDNA for 40 cycles with
melting for 5 s at 95uC, annealing for 5 s at 65uC and extension for
10 s at 72uC. Each reaction was performed in triplicate. Subsequent
assay efficiency calculations were carried out in Light Cycler
Relative Quantification Software (Roche Diagnostics). As the
efficiency of the target gene and the control genes were comparable,
DCp analysis of the results allows to assess the ratio of the target
mRNA versus control mRNA [39].
Data analysis
Statistical analysis was done with one-way ANOVA followed by
Student’s unpaired t-test using Statview software. In both cases,
Student-Newman-Keuls tests were used for multiple pairwise
comparaisons. The results are expressed as mean 6 SEM.
Correlations between Hcy level, DYRK1A protein expression
and SAHH activity were determined by using Spearman’s rank
correlation as data were not normally distributed according to
Shapiro – Wilk test. The multivariate analysis was performed
according to the principal component analysis (PCA). Data were
analyzed using R software (http://www.R-project.org) and
considered significant when p,0.05. A p value of 0.06–0.10 was
considered to indicate a strong statistical tendency due to the small
sample size.
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